This clinical trial is focused on studying a type of lung cancer known as Non-Small Cell Lung Cancer (NSCLC) that has a specific mutation called EGFR Exon 20ins. This mutation can make the cancer more challenging to treat. The study is testing a new treatment combination to see if it is more effective than the current standard treatment. The new treatment includes a medication called Amivantamab, which is being tested in combination with two chemotherapy drugs, Carboplatin and Pemetrexed. The purpose of the study is to compare how well patients do with the combination of Amivantamab and chemotherapy versus chemotherapy alone.

Participants in the study will receive their treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period to see how their cancer responds to the treatment. The main goal is to see if the new combination can help patients live longer without their cancer getting worse, which is known as progression-free survival.

This study is open-label, meaning both the researchers and participants know which treatment is being given. It is a randomized study, so participants are randomly assigned to receive either the new combination treatment or the standard chemotherapy. The study aims to provide more information on whether adding Amivantamab to the treatment plan can offer better outcomes for patients with this specific type of lung cancer.